BAJAJ FINSERV DIRECT LIMITED
Latest IPO Information

Asston Pharmaceuticals Ltd. IPO

IPO Date: Jul 9 to Jul 11 2025

Listing Date: Jul 16 2025

Objective

1. Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit;
2. Funding the incremental working capital requirements of our Company;
3. Repayment and/or prepayment, in part or full, of certain of our outstanding borrowings availed by ourCompany; and
4. General Corporate Purposes

IPO Details

Face Value ₹ 10.00 Per Share
Issue Size ₹ 18.47 - 19.75 Cr
Price Band ₹ 115.00 - ₹ 123.00 Per Share
Market LOT 2000 shares
Issue Type Book building

About Company

Our Company is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products indomestic and various African markets. Our Company operates under brand “Asston”. Presently, our Company is involved in thebusiness of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel andLotion) and Oral Powder (Sachet, Dry Syrup) etc. Apart from manufacturing products for direct sales, our Company alsomanufactures various pharmaceutical products for different marketers on loan license or on contract manufacturing basis .... . Ourbusiness is primarily conducted on a principle-to-principle basis with various marketers.As on the date, we cater to multiple corporate clients on loan licence and/or contract manufacturing basis. Currently, our Companyhas its production facility at Ambernath, Maharashtra, for producing generic medicines in the tablet form and nutraceuticalmedicines in the tablet form, syrup and sachet form. We have a dedicated and separate floors for pharmaceutical products andnutraceutical products respectively as the norms and standards are different for both of them and are governed by FDA and FSSAIrespectively. Since the FDA norms for pharmaceutical products are much more stringent, to comply with FDA standards separateguidelines are there to be followed. Facility has total production capacity of up to around 8-9 crore tablets per month. Our Companyproduces an average of 5-6 crore tablets per month, with production capacity varying based on the weight of the medicines. Higherweightmedicines result in lower production quantities and vice versa. The syrup production capacity for nutraceuticals isapproximately 37.5 kiloliters per month, while sachet production capacity ranges from 30 to 40 lakh sachets per month, dependingon the powder weight per sachet. The facility is certified by relevant authorities and undergoes periodic audits by state and centralFDA authorities. It includes a QA/QC unit and a warehouse for storing raw materials and finished goods in designated chambersunder controlled conditions. Our Company engages contract manufacturers to produce generic medicines and antibiotics in variousforms, including tablets, sachets, syrups, and capsules. All contract manufacturers are WHO-GMP certified to ensure their facilitiesand processes comply with applicable standards and industry norms. Read More
Address

-

City

-

State

-

Pincode

-

Phone

-

Email

-

Website

-

About IPO

Listed At BSE
Promoters
Ashish Narayan Sakalkar
Saili Jayaram More
Sachin Chandrakant Badakh

Promoter's Holding

Registrar

Maashitla Securities Pvt Ltd.

Latest News

Mar
2
2026
EQUITY Posted on Mar 2nd 2026

Asston Pharmaceuticals informs about appointment of statutory auditors

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Asston Pharmaceuticals has informed that the Board of Directors of the Company, on the recommendation of the Audit Committee and in due compliance with the provisions of Section 175 of the Companies Act, 2013 and the rules made thereunder, has accorded its approval by way of a resolution passed by circulation for the appointment of Panchal S K and Associates (Peer Review Certificate No. 018089 and Firm Registration No. 145989W) as the Statutory Auditors of the Company, subject to the approval of the shareholders of the Company at the ensuing General Meeting. The appointment has been made after due consideration of the firm’s professional standing, eligibility, and credentials, in accordance with the applicable provisions of the Companies Act, 2013 and the rules framed thereunder. The disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed as Annexure A and form an integral part of this intimation.’ In compliance with the provisions of Section 175 of the Companies Act, 2013, read with the rules made thereunder and other applicable laws for the time being in force, the delay in submission to the Exchange occurred due to the Company receiving the requisite approval of the majority of Directors on Friday, 27th February, 2026, after business hours. Thereafter, Saturday and Sunday, being non-working days, fell on 28th February, 2026, and 01st March, 2026, respectively. Accordingly, the said approval was intimated to the Exchange on the immediately succeeding working day, Monday, 02nd March, 2026. This disclosure complies with the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Read More
May
8
2026
EQUITY Posted on May 8th 2026

The Phoenix Mills informs about analyst meet

Pursuant to Regulation 30(6) read with Para A of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘Listing Regulations’), The Phoenix Mills has informed that the Company will be participating in the following Investor Interaction on Thursday, 14th May 2026 in Chennai organized by Avendus Spark, further details enclosed. This Intimation is also being uploaded on the Company’s website at: https://www.thephoenixmills.com/investors/FY2027/Exchange-Intimations.
The above information is a part of company’s filings submitted to BSE.
Read More
May
8
2026
EQUITY Posted on May 8th 2026

Ghushine Fintrrade Ocean informs about board meeting

In accordance with provisions of Regulation 29(1) (a) SEBI (LODR) Regulation, 2015, Ghushine Fintrrade Ocean has informed that meeting of Board of Directors of company is scheduled to be held on Thursday 14th May, 2026 at registered office of the company at Ground floor -27, Aagam Cross Road, AC Market opposite Star Galaxy near Shrungar Residency, Vesu Abhava road, Surat-395007 to consider and transact the business as stated in the notice of Board Meeting. The important item of agenda to be transacted at the meeting are: a. To consider and approve unaudited Half Yearly Financial Results for the half year ended on 31st march, 2026 with Limited Review Report. b. Any other business with the permission of Chair.

The above information is a part of company’s filings submitted to BSE.

Read More
May
8
2026
EQUITY Posted on May 8th 2026

Camlin Fine Sciences informs about voting results of postal ballot

In furtherance to letter dated April 7, 2026, for seeking consent of the Members of the Company by way of remote e‐voting process (‘e-voting’) through postal ballot for increase in Authorized Share Capital and Consequent Amendment to Clause V of the Memorandum of Association of the Company, Camlin Fine Sciences has informed that the above Resolution has been passed by the Members of the Company with requisite majority on May 7, 2026, being the last date of voting. The Voting results of the said Postal Ballot activity through remote e‐Voting, in relation to the aforesaid business, as required under Regulation 44 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 is enclosed. The Scrutinizer's Report dated May 8, 2026, pursuant to Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 is also enclosed. The Voting Results along with the Scrutinizer's Report are also available on the website of the Company: https://www.camlinfs.com/.

The above information is a part of company’s filings submitted to BSE.
Read More
May
8
2026
EQUITY Posted on May 8th 2026

Shakti Pumps India informs about disclosure

Shakti Pumps India has informed that it enclosed the Monitoring Agency Report dated 07.05.2026 issued by India Ratings & Research, Monitoring Agency, appointed by the Company, for the quarter ended March 31, 2026 in respect of utilization of fund raised through Qualified Institutions Placements (‘QIPs’) held on 22.03.2024 and 05.07.2025. The above information is also being made available on website of the Company at www.shaktipumps.com.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the issue size of Asston Pharmaceuticals Ltd. IPO?

The issue size of Asston Pharmaceuticals Ltd. IPO is ₹18.47 - 19.75 crore.

The Asston Pharmaceuticals Ltd. IPO opens for subscription on 2025-07-09 and closes on 2025-07-11.

The price range of Asston Pharmaceuticals Ltd. IPO is ₹115.00 to ₹123.00.

The lot size of Asston Pharmaceuticals Ltd. IPO is 2000 shares.

The registrar of Asston Pharmaceuticals Ltd. IPO is Maashitla Securities Pvt Ltd..

Asston Pharmaceuticals Ltd. IPO will be listed on BSE .

You will typically receive a confirmation message or notification from your broker or trading platform shortly after placing your IPO order. This confirms that your application has been submitted successfully. You can also check the order status in the IPO section of your trading account or app.

Apply early with valid UPI and PAN before 2025-07-11 to increase your chances.

The listing date of Asston Pharmaceuticals Ltd. IPO is 2025-07-16.

An Initial Public Offering (IPO) is when a private company sells shares to the public for the first time, enabling investors to purchase these shares and gain partial ownership in the business. For instance, if a well-known tech firm wants to grow and requires additional funds, it might choose to go public through an IPO. During this process, investors can buy shares, and the company’s stock starts trading on the stock exchange on the day of the IPO listing.

Investors can apply for an IPO through their bank or brokerage account. Many trading platforms have a specific section for IPOs where users can submit their applications online.

The primary market is where shares are offered to the public for the first time via an IPO. After the IPO, shares are traded on the secondary market (stock exchange), where existing shareholders can sell to new buyers.

Investing in an IPO offers the opportunity to become an early investor in companies with high growth potential, at a price which may be lower than their post-listing market value. It provides a chance to participate in the company's growth journey from its early stages. However, IPO investments also come with inherent risks, such as market volatility and uncertainties about the company's future performance.

The price of an IPO is established through a systematic process known as "book building." In this method, investors bid within a given price range, and the final price is set based on demand and market conditions. Several factors play a crucial role in determining the IPO price, including:

Past Financial Performance: Evaluating the company's revenue, profits, and financial stability over time

Growth Potential: Assessing future prospects based on the company's business model and market opportunities

Industry Peers: Comparing valuation metrics with similar companies in the same sector

Larger Industry Picture: Analysing overall industry trends and economic conditions that could impact the company's performance

The lock-in period for IPO shares refers to a duration during which specific investors are restricted from selling their shares post-listing. This period varies based on the type of investor:

Promoters: The lock-in period for promoters ranges from 6 months to 18 months, ensuring their commitment to the company's long-term growth

Anchor Investors: Typically, anchor investors face a shorter lock-in period of 30 to 90 days, depending on regulatory norms and the specific IPO

IPOs can be volatile and may not perform as expected in the short term. Investors risk losing capital if the stock price drops after listing, especially if the company does not meet its growth projections.

Information on upcoming IPOs is often available through brokerage platforms, financial news sites, and regulatory bodies like SEBI, which publishes details on companies going public. You can also get these details under the upcoming IPO section on Bajaj Markets.

Eligibility for an IPO typically includes:

Retail Investors: Individuals who invest in smaller amounts, usually under the “retail investor” category, with certain limits

Qualified Institutional Buyers (QIBs): Entities like mutual funds, banks, and insurance companies, who invest large sums

Non-Institutional Investors (NIIs): High-net-worth individuals or entities investing above the retail threshold

Investors must have a Demat and trading account to apply, and in some cases, certain financial or residency qualifications may apply depending on local regulations.

SME (Small and Medium Enterprise) IPOs generally carry higher risk but may provide significant growth potential. Investors should research the company’s stability, financials, and sector risks, as SME stocks can be more volatile compared to large-cap companies.

View More

Disclaimer

This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.

Invalid Mobile Number

Invalid Full Name

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore